Viome is an AI medical diagnostic service provider that understands the activities in the gut by analyzing the RNA of living organisms in the gut. Users only need to provide a stool sample, and Viome will test for microbes (viruses, bacteria, yeast and fungi), in addition to providing metabolic testing on-site services, but requires users to fill out a health questionnaire. Viome Life Sciences announced the completion of a $67 million Series C+ financing. The round, led by Bold Capital Group and joined by existing Viome investors, raised more than $67 million.
This article is reproduced from: https://www.itjuzi.com/investevent/13615028
This site is for inclusion only, and the copyright belongs to the original author.